RadNet Participates in Exciting Clinical Trials to Evaluate and Stage Prostate Cancer

RadNet Participates in Exciting Clinical Trials to Evaluate and Stage Prostate Cancer

RadNet’s Research Division has been participating in two clinical trials of a prostate-specific Positron Emission Tomography (PET) tracer in men with newly diagnosed prostate cancer and those with a recurrence of prostate cancer after having undergone previous prostate cancer treatment. Under the guidance of Judith Rose M.D., Medical Director of PET/CT and Clinical Research for RadNet, and in conjunction with Dr. David Josephson M.D. of Tower Urology, and Blue Earth Diagnostics. The intent of the trials  was to evaluate the rhPASMA tracer  to determine the extent and location of new and recurrent prostate cancer, in order to determine appropriate clinical management.

Lighthouse & Spotlight

The two studies are technically known as BED-PSMA-301 and BED-PSMA-302.  The names are Lighthouse and Spotlight. 

The Lighthouse study is investigating the safety and diagnostic performance of the PET PSMA tracer in men with newly diagnosed prostate cancer. Spotlight is investigating this same PSMA tracer in men with suspected prostate cancer recurrence, based on an elevated PSA level following prior therapy for prostate cancer.

These studies were being conducted in both the U.S. and Europe, at multiple centers.

What is a PET tracer?

Positron Emission Tomography, or PET, is an imaging technique that uses substances known as tracers to visualize and measure changes in processes as well as other physiological activities. These tracers are administered intravenously and different tracers are used for various purposes, depending on the specific disease of the patient and their clinical presentation. An example is FDG, and Axumin, which is another tracer used for detecting prostate cancer. Radnet was also involved in the LOCATE trial which was the pre-marketing approval study for Axumin 

Prostate Cancer

The prostate is a walnut-shaped gland that is part of the male reproductive system. It surrounds the urethra at the neck of the bladder and its main function is to make a fluid that goes into semen.

Prostate cancer begins when cells in the prostate gland start to grow out of control. Some prostate cancers can spread quickly, but most develop slowly.

Prostate cancer is the second most common cancer in men, affecting 1 in 9 men. Despite the prevalence of prostate cancer, it is highly treatable if detected early. Today, 3.1 million men living in the United States have been diagnosed with prostate cancer at some point.

RadNet Research

RadNet has a long history of participating in clinical trials and research programs. We partner with labs, medical companies and other physicians to test new technologies, equipment and cutting-edge treatments. The Lighthouse and the Spotlight trials have now completed enrollment and are currently closed to new patients if you are interested in learning more or seeing if you qualify to participate in a clinical trial, please visit www.clinicaltrials.gov.

View Our Centers

We Want To Hear From You

Prostate MRI

Call and we'll help schedule your Prostate MRI screening appointment and answer your questions.

Arizona: (480) 455-1850

Fresno: (559) 474-4290

Coachella Valley: (760) 318-2988

Victor Valley: (760) 951-2867

Inland Empire: (951) 682-1099

Antelope Valley: (661) 945-5855

Long Beach: (714) 784-1643

Los Angeles: (310) 854-7722

San Fernando Valley: (818) 616-6538

San Gabriel Valley: (626) 445-4850

Temecula Valley: (951) 587-8956

Ventura County: (805) 357-0067

Orange County: (714) 784-1643

Bakersfield: (661) 324-7000

TULSA Procedure

Call or submit the form to start the TULSA Procedure process with our team. We're here to guide you through each step and answer any questions you have.

TULSA Procedure Phone: (818) 480-7266

TULSA Procedure Fax: (818) 827-5152

Message Sent!